Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthetic Biology

Oligonucleotide therapeutics attract investment

by Shi En Kim
December 29, 2022 | A version of this story appeared in Volume 101, Issue 1

 

Oligonucleotides—short, synthetic nucleotide strands that can be used as drugs to modulate gene expression—were at the heart of two deals inked in December. Vertex Pharmaceuticals will pay Entrada Therapeutics $250 million and up to $485 million later to advance treatments for myotonic dystrophy type 1, including a preclinical oligonucleotide therapy from Entrada that potentially restores muscle function. And GSK will pay Wave Life Sciences $170 million up front plus future milestones and royalties as part of a pact to advance up to 11 oligonucleotide programs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.